8: Dosimetric Predictors of Toxicity and Quality of Life Following Single Fraction High Dose-Rate Prostate Brachytherapy

2021 ◽  
Vol 163 ◽  
pp. S7
Author(s):  
Mark T. Corkum ◽  
Andrew Loblaw ◽  
Hans T. Chung ◽  
Chia-Lin Tseng ◽  
Merrylee McGuffin ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Dose Rate ◽  
High Dose Rate ◽  
High Dose ◽  
Prostate Brachytherapy ◽  
Single Fraction

Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial

2018 ◽  
Vol 126 (2) ◽  
pp. 278-282 ◽  
Author(s):  
Alfonso Gomez-Iturriaga ◽  
Francisco Casquero ◽  
Jose Ignacio Pijoan ◽  
Pablo Minguez ◽  
Jose Maria Espinosa ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Dose Rate ◽  
Phase Ii Trial ◽  
High Dose Rate ◽  
High Dose ◽  
Prostate Brachytherapy ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer

2015 ◽  
Vol 41 (1) ◽  
pp. 40-45 ◽  
Author(s):  
Jessika A. Contreras ◽  
Richard B. Wilder ◽  
Eric A. Mellon ◽  
Tobin J. Strom ◽  
Daniel C. Fernandez ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Dose Rate ◽  
High Dose Rate ◽  
High Dose ◽  
High Dose Rate Brachytherapy

Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer

2015 ◽  
Vol 117 (2) ◽  
pp. 252-257 ◽  
Author(s):  
Shafak Aluwini ◽  
Wendy M.H. Busser ◽  
Wendimagegn Ghidey Alemayehu ◽  
Joost L. Boormans ◽  
Wim J. Kirkels ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Dose Rate ◽  
High Dose Rate ◽  
High Dose ◽  
Intermediate Risk ◽  
High Dose Rate Brachytherapy ◽  
Risk Prostate Cancer

scholarly journals Quality of life after high-dose rate brachytherapy monotherapy for prostate cancer.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 278-278
Author(s):  
Jessika Contreras ◽  
Richard Wilder ◽  
Eric Albert Mellon ◽  
Tobin Joel Crill Strom ◽  
Daniel Celestino Fernandez ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Dose Rate ◽  
High Dose Rate ◽  
High Dose ◽  
Intermediate Risk ◽  
Hdr Brachytherapy ◽  
Risk Prostate Cancer ◽  
A Prospective Study

278 Background: There is little information in the literature on health-related quality-of-life (HRQOL) changes due to high-dose-rate (HDR) brachytherapy monotherapy for prostate cancer. Methods: We conducted a prospective study of HRQOL changes due to HDR brachytherapy monotherapy for low risk or favorable intermediate risk prostate cancer. Forty-nine of 84 (58%) patients who were treated between February 2011 and April 2013 completed 50 questions comprising the Expanded Prostate Cancer Index Composite (EPIC) before treatment and 6 and/or 12 months after treatment. Results: Six months after treatment, there was a significant decrease (p<0.05) in EPIC urinary, bowel, and sexual scores, including urinary overall, urinary function, urinary bother, urinary irritative, bowel overall, bowel bother, sexual overall, and sexual bother scores. By one year after treatment, all EPIC scores had increased and were not significantly different from baseline values. Conclusions: HDR brachytherapy monotherapy is well-tolerated in patients with low and favorable intermediate risk prostate cancer. Urinary, bowel, and sexual domain scores returned to close to baseline 12 months after treatment.

High dose rate brachytherapy as a single 15 Gy fraction combined with hypofractionated external beam radiotherapy for intermediate-risk prostate cancer.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 66-66
Author(s):  
G. Morton ◽  
D. A. Loblaw ◽  
H. T. Chung
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Dose Rate ◽  
External Beam Radiotherapy ◽  
High Dose Rate ◽  
High Dose ◽  
External Beam ◽  
Intermediate Risk ◽  
Risk Prostate Cancer

66 Background: High dose rate (HDR) brachytherapy for prostate cancer is commonly given in multiple fractions combined with external beam radiotherapy (EBRT) over 5 weeks. We report results of a phase II clinical trial of single fraction HDR combined with hypofractionated EBRT over 3 weeks. Methods: Eligible patients had T1 or T2 carcinoma of the prostate with a PSA < 20 and Gleason score of 7 or less, without use of androgen deprivation. The trial accrued 125 patients with a median PSA of 6.8 ng/ml; 93% had Gleason 7. Single 15 Gy HDR was delivered to the prostate, followed 2-weeks later by EBRT to 37.5 Gy in 15 fractions. Patients were followed for toxicity (CTCAE v 3.0), health related quality of life (EPIC), urinary symptoms (IPSS), and clinical and biochemical control. Results: Median follow-up is 3 years (range: 1-4.5 years), with no biochemical failures. Median PSA at 3 years is 0.24 ng/ml. One of 38 biopsies at 2 years had persistent cancer. Two patients (1.6%) had acute grade 3 urinary toxicity, and median IPSS score returned to within 2 points of baseline by 3 months. The prevalence of grade 2 rectal and urinary toxicity at 2 years was 2% and 25%, respectively. Mean EPIC urinary and bowel domain scores decreased in the first 2 years, but returned to within 5 points of baseline at 3 years. Mean sexual function scores declined over the first 4 years although sexual bother scores returned to baseline at 3 years. On multivariate analysis, baseline IPSS score (p=0.0125), V100 (p=0.0002) and V200 (p=0.0141) were associated with acute grade 2 urinary toxicity. Decline in EPIC urinary quality of life domain was associated with HDR dose to 10% of urethra (p=0.0168), with a threshold of 120%. Decline in sexual scores was associated with smaller prostates and high baseline erectile functioning. Conclusions: Single fraction 15 Gy HDR combined with hypofractionated external beam radiotherapy is a well tolerated and effective treatment for intermediate risk prostate cancer. No significant financial relationships to disclose.

3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: A cross-sectional quality-of-life survey

2006 ◽  
Vol 45 (6) ◽  
pp. 708-716 ◽  
Author(s):  
Dirk Vordermark ◽  
Jörn Wulf ◽  
Klaus Markert ◽  
Kurt Baier ◽  
Oliver Kölbl ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Dose Rate ◽  
High Dose Rate ◽  
High Dose ◽  
Cross Sectional ◽  
High Dose Rate Brachytherapy ◽  
Brachytherapy Boost ◽  
Conformal Treatment
Sign in / Sign up

Export Citation Format

Share Document